Multimodal approach to assess the risk of heart failure in patients with acute myocardial infarction (Part 1). Clinical and laboratory predictors
https://doi.org/10.51922/2616-633X.2022.6.2.1592
Abstract
According to the Russian epidemiological study EPOСHA-CHF (1998–2017), during a 20-year follow-up, the prevalence of chronic heart failure (CHF) increased from 6.1 to 8.2%. Arterial hypertension, coronary heart disease, atrial fibrillation, diabetes mellitus remain the main causes of CHF. At the same time, acute myocardial infarction (AMI) as a cause of heart failure increased by 3 times. The median survival time among the patients with CHF I-II functional class (FC) is 8.4 years, and 3.8 years among the patients with CHF III-IV FC, which indicates a poor prognosis of CHF of any functional class. Currently, a number of clinical, biochemical, angiographic, and imaging approaches have been proposed to stratify the risk of CHF after AMI, but only a few of them are used in routine clinical practice. Given the increasing contribution of CHF to morbidity and mortality after myocardial infarction, early multimodal risk stratification is needed to develop preventive strategies aimed at averting this complication. This report presents current ideas about the role of clinical risk factors, biochemical and genetic markers of CHF, considered as early predictors of heart failure in patients with acute myocardial infarction.
About the Authors
N. Tsapaeva
Belarusian State Medical University
Belarus
Belarus
Minsk
S. Zolotuhina
Belarusian State Medical University
Belarus
Belarus
Minsk
Е. Mironova
Belarusian State Medical University
Belarus
Belarus
Minsk
I. Gajdukevich
Belarusian State Medical University
Belarus
Belarus
Minsk
V. Rodich
4th Savchenko City Clinical Hospital
Belarus
Belarus
Minsk
Е. Burakovskaja
4th Savchenko City Clinical Hospital
Belarus
Belarus
Minsk
References
1. Tsao C.W., Lyass A., Enserro D., Larson M.G., Ho J.E., Kizer J.R., Gottdiener J.S., Psaty B.M., Vasan R.S. Temporal Trends in the Incidence of and Mortality Associated with Heart Failure with Preserved and Reduced Ejection Fraction. JACC: Heart Failure, 2018, vol. 6, no. 8, pp.678–685. DOI: 10.1016/j.jchf.2018.03.006.
2. Vinogradova N.G., Polyakov D.S., Fomin I.V. Analysis of mortality in patients with heart failure after decompensation during longterm follow-up in specialized medical care and in real clinical practice [Analysis of mortality in patients with CHF after decompensation with long-term follow-up in specialized medical care and in real clinical practice]. Kardiologiia, 2020, vol. 60, no. 4, pp.91–100. (in Russian).
3. Shah K.S, Xu H., Matsouaka R.A., Bhatt D.L., Heidenreich P.A., Hernandez A.F., Devore A.D., Yancy C.W., Fonarow G.C. Heart Failure with Preserved, Borderline, and Reduced Ejection Fraction. J Am Coll Cardiol, 2017, vol. 70, no. 20, pp. 2476–2486. DOI: 10.1016/j.jacc. 2017.08.074.
4. Boytsov S.A., Balanova Yu.A., Shal’nova S.A., Deev A.D., Artamonova G.V., Gatago-nova T.M. [et al.] Arterial’naya gipertoniya sredi lic 25-64 let: rasprostranennost’, osvedomlennost’, lechenie i kontrol’. Po materialam issledovaniya ESSE [Arterial hypertension among people aged 25-64: prevalence, awareness, treatment and control. based on the materials of the ESSAY study.]. Kardiovaskulyarnaya terapiya i profilaktika, 2014, vol. 13, no. 4, pp. 4–14. DOI: 10.15829/1728-8800-2014-4-4-14. (in Russian).
5. Gerber Y., Weston S.A., Enriquez-Sarano M., Berardi C., Chamberlain A.M., Manemann S.M. [et al.] Mortality Associated with Heart Failure After Myocardial Infarction: A Contemporary Community Perspective. Circulation: Heart Failure, 2016, vol. 9, no. 1, pp. e002460. DOI: 10.1161/CIRCHEARTFAILURE.115.002460.
6. Xanthakis V., Enserro D.M., Larson M.G., Wollert K.C., Januzzi J.L., Levy D. [et al.] Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages in the Community. JACC: Heart Failure, 2016, vol. 4, no. 10, pp. 808–815. DOI: 10.1016/j.jchf.2016.05.00.
7. Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Badin Yu.V., Galyavich A.S. [et al.] Prevalence of CHF in European part of the Russian Federation: data from EPOCH-CHF [The prevalence of chronic heart failure in the European part of the Russian Federation. EPOCH–HSN data]. Russian Heart Failure Journal, 2006, vol. 7, no. 1, pp. 4–7. (in Russian).
8. Shechrbinina E.V., Badin Yu.V., Vaysberg A.R. Dynamics of the etiological causes of CHF formation in a representative sample of the Nizhny Novgorod region over 9 years of follow-up (1998-2007) [Dynamics of etiological causes of CHF formation in a representative sample of the Nizhny Novgorod region over 9 years of follow-up (1998-2007)]. All-Russian Conference of CHF: “Heart failure, 2007”. – M., 2007, pp. 38. (in Russian).
9. Benjamin E.J., Muntner P., Alonso A., Bittencourt M.S., Callaway C.W., Carson A.P. [et al.] Heart Disease and Stroke Statistics–2019 Update: A Report from the American Heart Association. Circulation, 2019, vol. 139, no. 10, pp. e56–528. DOI: 10.1161/CIR.0000000000000659]
10. Polyakov D.S., Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Artem’eva E.G., Badin Yu.V., Bakulina E.V., Vinogradova N.G., Galyavich A.S., Ionova T.S., Kamalov G.M., Kechedzhieva S.G., Koziolova N.A., Malenkova V.Yu., Mal’chikova S.V., Mareev Yu.V., Smirnova E.A., Tarlovskaya E.I., Shcherbinina E.V., Yakushin S.S. Hronicheskaya serdechnaya nedostatochnost’ v Rossijskoj Federacii: chto izmenilos’ za 20 let nablyudeniya? Rezul’taty issledovaniya EPOHA–HSN [Chronic heart failure in the russian federation: what has changed over 20 years of follow-up? Results of the epoch-chf study]. Kardiologiya, 2021, vol. 61, no. 4, pp. 4–14. DOI: 10.18087/cardio.2021.4.n1628. (in Russian).
11. Steg P.G., Dabbous O.H., Feldman L.J., Cohen-Solal A., Aumont M.C., López-Sendón J., Budaj A., Goldberg R.J., Klein W., Anderson F.A. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation, 2004, vol. 109, pp. 494–499.
12. DeGeare V.S., Boura J.A., Grines L.L., O’Neill W.W., Grines C.L. Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol, 2001, vol. 87, pp. 1035–1038.
13. Nicod P., Gilpin E., Dittrich H., Chappuis F., Ahnve S., Engler R., Henning H., Ross J. Influence on prognosis and morbidity of left ventricular ejection fraction with and without signs of left ventricular failure after acute myocardial infarction. Am J Cardiol, 1988, vol. 61, pp. 1165–1171.
14. Braunwald E. Heart failure. JACC Heart Fail, 2013, vol. 1, no. 1, pp. 1–20. doi: 10.1016/j.jchf.2012.10.002.
15. Heusch G., Gersh B.J. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. Eur Heart J, 2017, vol. 38, pp. 774–784.
16. Sulo G., Igland J., Vollset S.E., Nygård O., Ebbing M., Sulo E., Egeland G.M., Tell G.S. Heart failure complicating acute myocardial infarction, vol. burden and timing of occurrence: a nation-wide analysis including 86 771 patients from the cardiovascular disease in Norway (CVDNOR) project. J Am Heart Assoc, 2016, vol. 5, no. 1, pp. e002667.
17. Wellings J., Kostis J.B., Sargsyan D., Cabrera J., Kostis W.J. Risk factors and trends in incidence of heart failure following acute myocardial infarction. Am J Cardiol, 2018, vol. 122, no. 1, pp. 1–5.
18. Desta L., Jernberg T., Lofman I., Hofman-Bang C., Hagerman I., Spaak J., Persson H. Incidence, temporal trends, and prognostic impact of heart failure complicating acute myocardial infarction. The SWEDEHEART Registry (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies): a study of 199,851 patients admitted with index acute myocardial infarctions, 1996 to 2008. JACC Heart Fail, 2015, vol. 3, no. 3, pp. 234–242.
19. Kelly D.J., Gershlick T., Witzenbichler B., Guagliumi G., Fahy M., Dangas G., Mehran R., Stone G.W. Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. Am Heart J, 2011, vol. 162, no. 4, pp. 663–670.
20. Shaw L.J., Bairey Merz C.N., Pepine C.J., Reis S.E., Bittner V., Kelsey S.F., Olson M., Johnson B.D., Mankad S., Sharaf B.L., Rogers W.J., Wessel T.R., Arant C.B., Pohost G.M., Lerman A., Quyyumi A.A., Sopko G. Insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol, 2006, vol. 47, suppl. 3. S4–S20.
Review
For citations:
Tsapaeva N., Zolotuhina S., Mironova Е., Gajdukevich I., Rodich V., Burakovskaja Е. Multimodal approach to assess the risk of heart failure in patients with acute myocardial infarction (Part 1). Clinical and laboratory predictors. Emergency Cardiology and Cardiovascular Risks journal. 2022;6(2):1592-1603. (In Russ.) https://doi.org/10.51922/2616-633X.2022.6.2.1592
Views:
6
Email this article 